Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 103

1.

ETS transcription factors as emerging drug targets in cancer.

Hsing M, Wang Y, Rennie PS, Cox ME, Cherkasov A.

Med Res Rev. 2019 Mar 29. doi: 10.1002/med.21575. [Epub ahead of print] Review.

PMID:
30927317
2.

Computer-Aided Discovery of Small Molecules Targeting the RNA Splicing Activity of hnRNP A1 in Castration-Resistant Prostate Cancer.

Carabet LA, Leblanc E, Lallous N, Morin H, Ghaidi F, Lee J, Rennie PS, Cherkasov A.

Molecules. 2019 Feb 20;24(4). pii: E763. doi: 10.3390/molecules24040763.

3.

IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling.

Sheng X, Nenseth HZ, Qu S, Kuzu OF, Frahnow T, Simon L, Greene S, Zeng Q, Fazli L, Rennie PS, Mills IG, Danielsen H, Theis F, Patterson JB, Jin Y, Saatcioglu F.

Nat Commun. 2019 Jan 24;10(1):323. doi: 10.1038/s41467-018-08152-3.

4.

Therapeutic Inhibition of Myc in Cancer. Structural Bases and Computer-Aided Drug Discovery Approaches.

Carabet LA, Rennie PS, Cherkasov A.

Int J Mol Sci. 2018 Dec 29;20(1). pii: E120. doi: 10.3390/ijms20010120. Review.

5.

Computer-Aided Discovery of Small Molecule Inhibitors of Transcriptional Activity of TLX (NR2E1) Nuclear Receptor.

Dueva E, Singh K, Kalyta A, LeBlanc E, Rennie PS, Cherkasov A.

Molecules. 2018 Nov 14;23(11). pii: E2967. doi: 10.3390/molecules23112967.

6.

Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.

Carabet LA, Lallous N, Leblanc E, Ban F, Morin H, Lawn S, Ghaidi F, Lee J, Mills IG, Gleave ME, Rennie PS, Cherkasov A.

Eur J Med Chem. 2018 Dec 5;160:108-119. doi: 10.1016/j.ejmech.2018.09.023. Epub 2018 Sep 11.

PMID:
30326371
7.

Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.

Dalal K, Morin H, Ban F, Shepherd A, Fernandez M, Tam KJ, Li H, LeBlanc E, Lack N, Prinz H, Rennie PS, Cherkasov A.

Eur J Med Chem. 2018 Sep 5;157:1164-1173. doi: 10.1016/j.ejmech.2018.08.059. Epub 2018 Aug 24.

PMID:
30193215
8.

Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.

Dalal K, Ban F, Li H, Morin H, Roshan-Moniri M, Tam KJ, Shepherd A, Sharma A, Peacock J, Carlson ML, LeBlanc E, Perez C, Duong F, Ong CJ, Rennie PS, Cherkasov A.

Cancer Lett. 2018 Nov 28;437:35-43. doi: 10.1016/j.canlet.2018.08.016. Epub 2018 Aug 27.

PMID:
30165195
9.

Toxic Colors: The Use of Deep Learning for Predicting Toxicity of Compounds Merely from Their Graphic Images.

Fernandez M, Ban F, Woo G, Hsing M, Yamazaki T, LeBlanc E, Rennie PS, Welch WJ, Cherkasov A.

J Chem Inf Model. 2018 Aug 27;58(8):1533-1543. doi: 10.1021/acs.jcim.8b00338. Epub 2018 Aug 15.

PMID:
30063345
10.

20(S)-protopanaxadiol regio-selectively targets androgen receptor: anticancer effects in castration-resistant prostate tumors.

Ben-Eltriki M, Deb S, Hassona M, Meckling G, Fazli L, Chin MY, Lallous N, Yamazaki T, Jia W, Rennie PS, Cherkasov A, Tomlinson Guns ES.

Oncotarget. 2018 Apr 20;9(30):20965-20978. doi: 10.18632/oncotarget.24695. eCollection 2018 Apr 20.

11.

Cheminformatics Driven Development of Novel Therapies for Drug Resistant Prostate Cancer.

Ban F, Dalal K, LeBlanc E, Morin H, Rennie PS, Cherkasov A.

Mol Inform. 2018 Sep;37(9-10):e1800043. doi: 10.1002/minf.201800043. Epub 2018 May 7. Review.

PMID:
29733509
12.

Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers.

Singh K, Munuganti RSN, Lallous N, Dalal K, Yoon JS, Sharma A, Yamazaki T, Cherkasov A, Rennie PS.

Int J Mol Sci. 2018 Feb 15;19(2). pii: E579. doi: 10.3390/ijms19020579.

13.

A TRAMP-derived orthotopic prostate syngeneic (TOPS) cancer model for investigating anti-tumor treatments.

Lardizabal J, Ding J, Delwar Z, Rennie PS, Jia W.

Prostate. 2018 May;78(6):457-468. doi: 10.1002/pros.23490. Epub 2018 Feb 16. Erratum in: Prostate. 2018 Sep;78(12):949.

PMID:
29450905
14.

Oncolytic Virotherapy Blockade by Microglia and Macrophages Requires STAT1/3.

Delwar ZM, Kuo Y, Wen YH, Rennie PS, Jia W.

Cancer Res. 2018 Feb 1;78(3):718-730. doi: 10.1158/0008-5472.CAN-17-0599. Epub 2017 Nov 8.

15.

Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.

Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, Yang YC, Nyquist MD, Mostaghel E, Hsieh AC, Zhang X, Corey E, Brown LG, Nguyen HM, Pienta K, Ittmann M, Schweizer M, True LD, Wise D, Rennie PS, Vessella RL, Morrissey C, Nelson PS.

Cancer Cell. 2017 Oct 9;32(4):474-489.e6. doi: 10.1016/j.ccell.2017.09.003.

16.

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer.

Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, Baridi A, Warren AY, Zhao W, Ogris C, McDuffus LA, Mascalchi P, Shaw G, Dev H, Wadhwa K, Wijnhoven P, Forment JV, Lyons SR, Lynch AG, O'Neill C, Zecchini VR, Rennie PS, Baniahmad A, Tavaré S, Mills IG, Galanty Y, Crosetto N, Schultz N, Neal D, Helleday T.

Nat Commun. 2017 Aug 29;8(1):374. doi: 10.1038/s41467-017-00393-y.

17.

Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions.

Dalal K, Che M, Que NS, Sharma A, Yang R, Lallous N, Borgmann H, Ozistanbullu D, Tse R, Ban F, Li H, Tam KJ, Roshan-Moniri M, LeBlanc E, Gleave ME, Gewirth DT, Dehm SM, Cherkasov A, Rennie PS.

Mol Cancer Ther. 2017 Oct;16(10):2281-2291. doi: 10.1158/1535-7163.MCT-17-0259. Epub 2017 Aug 3.

18.

Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.

Butler MS, Roshan-Moniri M, Hsing M, Lau D, Kim A, Yen P, Mroczek M, Nouri M, Lien S, Axerio-Cilies P, Dalal K, Yau C, Ghaidi F, Guo Y, Yamazaki T, Lawn S, Gleave ME, Gregory-Evans CY, McIntosh LP, Cox ME, Rennie PS, Cherkasov A.

Oncotarget. 2017 Jun 27;8(26):42438-42454. doi: 10.18632/oncotarget.17124.

19.

Best Practices of Computer-Aided Drug Discovery: Lessons Learned from the Development of a Preclinical Candidate for Prostate Cancer with a New Mechanism of Action.

Ban F, Dalal K, Li H, LeBlanc E, Rennie PS, Cherkasov A.

J Chem Inf Model. 2017 May 22;57(5):1018-1028. doi: 10.1021/acs.jcim.7b00137. Epub 2017 May 4.

PMID:
28441481
20.

c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks.

Barfeld SJ, Urbanucci A, Itkonen HM, Fazli L, Hicks JL, Thiede B, Rennie PS, Yegnasubramanian S, DeMarzo AM, Mills IG.

EBioMedicine. 2017 Apr;18:83-93. doi: 10.1016/j.ebiom.2017.04.006. Epub 2017 Apr 5.

Supplemental Content

Loading ...
Support Center